Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

U.S. Court Backs U.S. FDA Over Wyeth's Plea To Protect Zosyn From Orchid's Generic Copies

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - In a blow to Wyeth in its attempts to protect anti-bacterial combination injection Zosyn (piperacillin/tazobactum), the U.S. District Court of Columbia dismised a plea for a temporary restraining order against the U.S. FDA's decision to approve generic copies of the drug from India's Orchid Chemicals

You may also be interested in...



Hospira To Acquire Injectable Drug Business Of India's Orchid Pharmaceuticals

WASHINGTON - Hospira announced Dec. 15 it will purchase Orchid Chemicals & Pharmaceuticals' generic injectable drug business for $400 million, thereby filling one gap in the company's broadening therapeutic coverage

Hospira To Acquire Injectable Drug Business Of India's Orchid Pharmaceuticals

WASHINGTON - Hospira announced Dec. 15 it will purchase Orchid Chemicals & Pharmaceuticals' generic injectable drug business for $400 million, thereby filling one gap in the company's broadening therapeutic coverage

Wyeth To See First Copies Of Tazocin In EU From Orchid Chemicals

MUMBAI - U.S. drug maker Wyeth will see its first competition in Europe for key antibiotic drug Zosyn, or Tazocin, from Indian drug maker Orchid Chemicals. After almost a wait of more than a year, Orchid received approvals or Marketing Authorization for piperacillin/tazobactum injectibles in the EU countries

Latest Headlines
See All
UsernamePublicRestriction

Register

SC072866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel